3 results about "Lorcaserin" patented technology

To provide anti-obesity agents to overcome defects of currently used anti-obesity agents, that is, as main types of the previously developed anti-obesity drugs, appetite suppressants acting on the central nervous system are drugs that control the action of neurotransmitters (for example, phentermine, mazindol, lorcaserin, fluoxetine and sibutramine) were mostly used, but the neurotransmitter modulators exert a wide range of effects on various physiological actions in addition to appetite suppression by numerous subtype receptors, so that the modulators are lacking in selectivity for each subtype and have a large disadvantage in that various side effects are accompanied in a case of long-term administration.SOLUTION: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.SELECTED DRAWING: None

The present application belongs to the technical field of bio-chemical industry, and particularly relates to a lorcaserin artificial hapten, a lorcaserin artificial antigen, and a preparation method and application thereof. The lorcaserin hydrochloride is used as a starting material for synthesizing the artificial hapten, the lorcaserin artificial hapten of the present application retains the characteristic structure of lorcaserin to the greatest extent, and has an active group which can be coupled with a carrier protein, and can be used as an antigenic determinant; the lorcaserin artificial antigen prepared further can be used for immunization to obtain an anti-lorcaserin artificial antibody with high affinity, high sensitivity and high specificity, the titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:256000, and the immune serum can be used for rapid and accurate immunodetection and immunological analysis of lorcaserin.

The application discloses a kind of pharmaceutical composition and its purposes in preparation for inhibiting the autonomous intake preference of ethanol. The pharmaceutical composition includes lorcaserin and midazolam. The pharmaceutical composition for inhibiting the autonomous intake preference of ethanol provided by the application can effectively reduce the desire of body to alcohol, is used to treat alcohol dependence, and has significant long-acting characteristics. When the pharmaceutical composition is administered to mice, the absolute amount of active ethanol intake of mice and the relative proportion of ethanol intake compared with the amount of drinking water can be significantly reduced, and the inhibitory effect can last at least 6 days, which is expected to update the treatment plan for alcohol addiction in clinic.